Huperzine B

Identification

Generic Name
Huperzine B
DrugBank Accession Number
DB03348
Background

Huperzine B is a novel acetylcholinesterase inhibitor.

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 256.3428
Monoisotopic: 256.157563272
Chemical Formula
C16H20N2O
Synonyms
  • HupB

Pharmacology

Indication

Under investigation for the treatment of Alzheimer's disease.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Huperzine B is an alkaloid derived from Huperzia serrata (which is available as an herbal product in the US). It is under investigation as an acetylcholinesterase inhibitor. Clinical trials in China have shown that huperzine B is comparably effective to the drugs currently on the market, and may even be somewhat safer in terms of side effects.

Mechanism of action

Huperzine B has been found to be an inhibitor of the enzyme acetylcholinesterase. This is the same mechanism of action of pharmaceutical drugs such as galantamine and donepezil used to treat Alzheimer's disease.

TargetActionsOrganism
UAcetylcholinesteraseNot AvailableHumans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as phenanthrolines. These are aromatic polycyclic compounds containing the phenanthroline skeleton, which is a derivative of phenanthrene, and consists of two pyridine rings non-linearly joined by a benzene ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Phenanthrolines
Sub Class
Not Available
Direct Parent
Phenanthrolines
Alternative Parents
Quinolones and derivatives / Pyridinones / Aralkylamines / Piperidines / Heteroaromatic compounds / Lactams / Dialkylamines / Azacyclic compounds / Organooxygen compounds / Organic oxides
show 1 more
Substituents
1,7-phenanthroline / Amine / Aralkylamine / Aromatic heteropolycyclic compound / Azacycle / Heteroaromatic compound / Hydrocarbon derivative / Lactam / Organic nitrogen compound / Organic oxide
show 9 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
DC3Z5425Y5
CAS number
103548-82-9
InChI Key
YYWGABLTRMRUIT-HWWQOWPSSA-N
InChI
InChI=1S/C16H20N2O/c1-10-7-11-8-14-13(4-5-15(19)18-14)16(9-10)12(11)3-2-6-17-16/h4-5,7,11-12,17H,2-3,6,8-9H2,1H3,(H,18,19)/t11-,12+,16+/m0/s1
IUPAC Name
(1R,9R,10R)-16-methyl-6,14-diazatetracyclo[7.5.3.0^{1,10}.0^{2,7}]heptadeca-2(7),3,16-trien-5-one
SMILES
[H][C@]12CCCN[C@]11CC(C)=C[C@H]2CC2=C1C=CC(=O)N2

References

General References
  1. Zhang HY, Tang XC: Huperzine B, a novel acetylcholinesterase inhibitor, attenuates hydrogen peroxide induced injury in PC12 cells. Neurosci Lett. 2000 Sep 29;292(1):41-4. [Article]
  2. Feng S, Xia Y, Han D, Zheng C, He X, Tang X, Bai D: Synthesis and acetylcholinesterase inhibition of derivatives of huperzine B. Bioorg Med Chem Lett. 2005 Feb 1;15(3):523-6. [Article]
  3. He XC, Feng S, Wang ZF, Shi Y, Zheng S, Xia Y, Jiang H, Tang XC, Bai D: Study on dual-site inhibitors of acetylcholinesterase: Highly potent derivatives of bis- and bifunctional huperzine B. Bioorg Med Chem. 2007 Feb 1;15(3):1394-408. Epub 2006 Nov 9. [Article]
KEGG Compound
C09866
PubChem Compound
5462442
PubChem Substance
175426855
ChemSpider
16744040
BindingDB
50199518
ChEMBL
CHEMBL245079
ZINC
ZINC000003872828
PDBe Ligand
HUB
PDB Entries
1gpn

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP0.67Chemaxon
pKa (Strongest Acidic)11.22Chemaxon
pKa (Strongest Basic)9.77Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count2Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area41.13 Å2Chemaxon
Rotatable Bond Count0Chemaxon
Refractivity78.06 m3·mol-1Chemaxon
Polarizability28.42 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9953
Blood Brain Barrier+0.9465
Caco-2 permeable-0.537
P-glycoprotein substrateSubstrate0.8401
P-glycoprotein inhibitor INon-inhibitor0.6301
P-glycoprotein inhibitor IINon-inhibitor0.8246
Renal organic cation transporterNon-inhibitor0.5913
CYP450 2C9 substrateNon-substrate0.8044
CYP450 2D6 substrateNon-substrate0.7676
CYP450 3A4 substrateSubstrate0.6455
CYP450 1A2 substrateNon-inhibitor0.5655
CYP450 2C9 inhibitorNon-inhibitor0.5898
CYP450 2D6 inhibitorNon-inhibitor0.7528
CYP450 2C19 inhibitorNon-inhibitor0.5068
CYP450 3A4 inhibitorNon-inhibitor0.8313
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5088
Ames testNon AMES toxic0.682
CarcinogenicityNon-carcinogens0.9566
BiodegradationNot ready biodegradable0.9931
Rat acute toxicity2.7113 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9721
hERG inhibition (predictor II)Inhibitor0.5546
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a4i-0090000000-fe0ebee54707c402eb65
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a4i-0090000000-9775b0eef3d24c10c666
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4i-0090000000-ebc03f5a2bc020292e85
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-03di-0930000000-8d64263f80e9a955ac16
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4i-0090000000-d1176a6e86a09f3f6625
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-06tr-3390000000-3e6ca3106d26bc4995f6
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-165.4250291
predicted
DarkChem Lite v0.1.0
[M-H]-163.3949
predicted
DeepCCS 1.0 (2019)
[M+H]+165.7610291
predicted
DarkChem Lite v0.1.0
[M+H]+165.75288
predicted
DeepCCS 1.0 (2019)
[M+Na]+165.6310291
predicted
DarkChem Lite v0.1.0
[M+Na]+172.04662
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details
1. Acetylcholinesterase
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Serine hydrolase activity
Specific Function
Terminates signal transduction at the neuromuscular junction by rapid hydrolysis of the acetylcholine released into the synaptic cleft. Role in neuronal apoptosis.
Gene Name
ACHE
Uniprot ID
P22303
Uniprot Name
Acetylcholinesterase
Molecular Weight
67795.525 Da
References
  1. He XC, Feng S, Wang ZF, Shi Y, Zheng S, Xia Y, Jiang H, Tang XC, Bai D: Study on dual-site inhibitors of acetylcholinesterase: Highly potent derivatives of bis- and bifunctional huperzine B. Bioorg Med Chem. 2007 Feb 1;15(3):1394-408. Epub 2006 Nov 9. [Article]
  2. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]

Drug created at June 13, 2005 13:24 / Updated at June 12, 2020 16:52